Biomarkers for osteonecrosis in Gaucher disease

Bibliography

• Sly WS, Kaplan A, Achord DT, Receptor-mediated uptake of lysosomal enzymes. Prog Clin Biol Res 1978;23:547-51
   PubMedGoogle Scholar
• Barton NW, Brady RO, Dambrosia JM, Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324(21):1464-70
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G, Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122(1):33-9
   PubMed Web of Science ®Google Scholar
• Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 1997;10(4):657-89
   PubMedGoogle Scholar
• Cox T. Gaucher's disease - an exemplary monogenic disorder (Editorial). Q J Med 2001;94:399-402
   Google Scholar
• Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Valle D, Beudet A, Sly WS, editors. The metabolic and molecular bases of inherited diseases. New York: McGraw-Hill 2001. p. 3635-68
   Google Scholar
• Stowens D, Teitelbaum SL, Kahn AJ, Skeletal complications of Gaucher disease. Medicine 1985;64(5):310-22
   PubMed Web of Science ®Google Scholar
• Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002;75(1):A2-12
   PubMedGoogle Scholar
• Cox TM, Aerts JM, Belmatoug N, Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008;31(3):319-36
   PubMed Web of Science ®Google Scholar
• Giraldo P, Solano V, Perez-Calvo JI, Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 2005;14(2):453-62
   PubMed Web of Science ®Google Scholar
• Sims KB, Pastores GM, Weinreb NJ, Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 2008;73(5):430-40
   PubMed Web of Science ®Google Scholar
• de Fost M, van Noesel CJ, Aerts JM, Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 2008;93(7):1119-20
   PubMed Web of Science ®Google Scholar
• Mistry PK, Deegan P, Vellodi A, Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 2009;147(4):561-70
   PubMed Web of Science ®Google Scholar
• Deegan PB, Pavlova EV, Tindall J, Osseous manifestations of adult Gaucher Disease in the Era of enzyme replacement therapy. Medicine 2011;90(1):52-60
   PubMed Web of Science ®Google Scholar
• Charrow J, Dulisse B, Grabowski GA, The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007;71(3):205-11
   PubMed Web of Science ®Google Scholar
• Lafforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine 2006;73(5):500-7
   PubMed Web of Science ®Google Scholar
• Kenzora JE, Glimcher MJ. Accumulative cell stress: the multifactorial etiology of idiopathic osteonecrosis. Orthop Clin North Am 1985;16:669-79
   PubMed Web of Science ®Google Scholar
• Jones JP. Fat embolism and osteonecrosis. Orthop Clin North Am 1985;16:595-633
   PubMed Web of Science ®Google Scholar
• Jones LC, Mont MA, Le TB, Procoagulants and osteonecrosis. J Rheumatol 2003;30:783-91
   PubMed Web of Science ®Google Scholar
• Cox TM. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 2001;24(2):106-21
   PubMedGoogle Scholar
• Allen MJ, Myer BJ, Khokher AM, Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased of onterleukin-6 and interleukin-10. QJM 1997;90(1):19-25
   PubMed Web of Science ®Google Scholar
• Arlet J. Nontraumatic avascular necrosis of the femoral head. Past, present and future. Clin Orthop Relat Res 1992;277:12-21
   PubMed Web of Science ®Google Scholar
• Kokubo T, Takatori Y, Ninmiya S, Magnetic resonance imaging and scintigraphy of avascular necrosis of the femoral head. Clin Orthop Relat Res 1992;277:54-60
   PubMedGoogle Scholar
• Saito S, Ohzono K, Ono K. Early arteriopathy and postulated pathogenesis of osteonecrosis of the femoral head. Clin Orthop Relat Res 1992;277:98-110
   PubMedGoogle Scholar
• Matsui M, Saito S, Ohzono K, Experimental steroid-induced osteonecrosis in adult rabbits with hypersensitivity vasculitis. Clin Orthop Relat Res 1992;277:61-72
   PubMedGoogle Scholar
• Atsumi T, Kuroki Y. Role of impairment of blood supply of the femoral head in the pathogenesis of idiopathic osteonecnosis. Clin Orthop Relat Res 1992;277:22-30
   PubMedGoogle Scholar
• Jones J. Intravascular coagulation and osteonecrosis. Clin Orthop Relat Res 1992;277:41-53
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Freiberg RA, Fontaine RN, Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res 2001;386:19-33
   PubMed Web of Science ®Google Scholar
• Hollak CE, van Weely S, van Oers MH, Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93(3):1288-92
   PubMed Web of Science ®Google Scholar
• Boot RG, Verhoek M, de Fost M, Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004;103(1):33-9
   PubMed Web of Science ®Google Scholar
• Deegan PB, Moran MT, McFarlane I, Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 2005;35(2):259-67
   PubMed Web of Science ®Google Scholar
• Aerts JM, Hollak CE. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 1997;10(4):691-709
   PubMedGoogle Scholar
• Cabrera-Salazar MA, O'Rourke E, Henderson N, Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 2004;344(1-2):101-7
   PubMed Web of Science ®Google Scholar
• Gelfand G, Bienenstock H. Hemorrhagic bursitis and bone crises in chronic adult Gaucher's disease: a case report. Arthritis Rheum 1982;25:1369
   PubMed Web of Science ®Google Scholar
• Goldblatt J, Sacks S, Beighton P. The orthopedic aspects of Gaucher disease. Clin Orthop Relat Res 1978;137:208
   PubMedGoogle Scholar
• Amstutz H. The hip in Gaucher's disease. Clin Orthop Relat Res 1973;90:183
   PubMedGoogle Scholar
• Yossipovitch ZH, Herman G, Makin M. Aseptic osteomyelitis in Gaucher's disease. Isr J Med Sci 1965;1(4):531-6
   PubMedGoogle Scholar
• Rodrigue SW, Rosenthal DI, Barton NW, Risk factors for osteonecrosis in patients with type 1 Gaucher's disease. Clin Orthop Relat Res 1999(362):201-7
   PubMed Web of Science ®Google Scholar
• Fleshner PR, Aufses AH Jr, Grabowski GA, A 27-year experience with splenectomy for Gaucher's disease. Am J Surg 1991;161:69-75
   PubMed Web of Science ®Google Scholar
• Charrow J, Andersson HC, Kaplan P, The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160(18):2835-43
   PubMed Web of Science ®Google Scholar
• Piran S, Roberts A, Patterson MA, The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations. Blood Cells Mol Dis 2009;43(3):289-93
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Charrow J, Andersson HC, Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113(2):112-19
   PubMed Web of Science ®Google Scholar
• Cox TM, Aerts JM, Andria G, The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. Advisory Council to the European Working Group on Gaucher Disease. J Inherit Metab Dis 2003;26(6):513-26
   PubMed Web of Science ®Google Scholar
• Platt FM, Neises GR, Dwek RA, N-butyldeoxnojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 1994;269(11):8362-5
   PubMed Web of Science ®Google Scholar
• Butters TD, van den Broek LAGM, Fleet GWJ, Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis. Tetrahedron Asymmetry 2000;11(1):113-24
   Web of Science ®Google Scholar
• Cox T, Lachmann R, Hollak C, Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355(9214):1481-5
   PubMed Web of Science ®Google Scholar
• Elstein D, Hollak C, Aerts JM, Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004;27(6):757-66
   PubMed Web of Science ®Google Scholar
• Heitner R, Elstein D, Aerts J, Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002;28(2):127-33
   PubMed Web of Science ®Google Scholar
• Pastores GM, Elstein D, Hrebicek M, Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther 2007;29(8):1645-54
   PubMed Web of Science ®Google Scholar
• Giraldo P, Alfonso P, Atutxa K, Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica 2009;94(12):1771-5
   PubMed Web of Science ®Google Scholar
• Roca M, Mota J, Alfonso P, S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease. Eur J Radiol 2007;62:132-7
   PubMed Web of Science ®Google Scholar
• Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type 1 Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005;27(8):1215-27
   PubMed Web of Science ®Google Scholar
• McEachern KA, Fung J, Komarnitsky S, A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 2007;91(3):259-67
   PubMed Web of Science ®Google Scholar
• Cox TM. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs 2010;11(10):1169-81
   PubMed Web of Science ®Google Scholar
• Lukina E, Watman N, Arreguin EA, A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010;116(6):893-9
   PubMed Web of Science ®Google Scholar
• Lukina E, Watman N, Avila Arreguin E, Improvement in hematological, visceral and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz 112638) treatment: two-year results of a phase 2 study. Blood 2010;116(20):4095-8
   PubMed Web of Science ®Google Scholar
• Bembi B, Agosti E, Boehm P, Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3. Acta Paediatr 1994;83:122-4
   PubMed Web of Science ®Google Scholar
• Ciana G, Cuttini M, Bembi B. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement. N Engl J Med 1997;337:712
   PubMed Web of Science ®Google Scholar
• Ostlere L, Warner T, Meunier PJ, Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate). Q J Med 1991;79:503-15
   PubMedGoogle Scholar
• Marx RE, Sawatari Y, Fortin M, Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75
   PubMed Web of Science ®Google Scholar
• Barasch A, Cunha-Cruz J, Curro FA, Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 2011;90:439-44
   PubMed Web of Science ®Google Scholar
• Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people. J Am Dent Assoc 2008;139:23-30
   PubMed Web of Science ®Google Scholar
• Grbic JT, Landesberg R, Lin SQ, Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139:32-40
   PubMed Web of Science ®Google Scholar
• Khan AA, Sandor GK, Dore E, Canadian Association of Oral and Maxillofacial Surgeons. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35:1391-7. Erratum in: J Rheumatol 35: 1688 and 2084
   PubMed Web of Science ®Google Scholar
• Subramanian G, Cohen HV, Quek SY. A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; published online 6 August; doi:10.1016/j.tripleo.2011.04.020
   PubMed Web of Science ®Google Scholar
• Moran MT, Schofield JP, Hayman AR, Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000;96(5):1969-78
   PubMed Web of Science ®Google Scholar
• Boven LA, van Meurs M, Boot RG, Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004;122(3):359-69
   PubMed Web of Science ®Google Scholar
• Michelakakis H, Dimitriou E, Van Weely S, Plasma tumor necrosis factor-a (THF-alpha) levels in Gaucher disease. Biochim Biophys Acta 1996;1317(3):219-22
   PubMed Web of Science ®Google Scholar
• Hollak CE, Evers L, Aerts JM, Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 1997;23(2):201-12
   PubMed Web of Science ®Google Scholar
• Kodelja V, Muller C, Politz O, Alternative macrophage activation associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998;160(3):1411-18
   PubMed Web of Science ®Google Scholar
• van Breemen MJ, de Fost M, Voerman JS, Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 2007;1772(7):788-96
   PubMed Web of Science ®Google Scholar
• Pavlova EV, Deegan PB, Tindall J, Potential biomarkers of osteonecrosis in Gaucher disease. Blood Cells Mol Dis 2011;46(1):27-33
   PubMed Web of Science ®Google Scholar
• Lichtenstein M, Zimran A, Horowitz M. Cytokine mRNA in Gaucher disease. Blood Cells Mol Dis 1997;23(3):395-401
   PubMedGoogle Scholar
• Campeau PM, Rafei M, Boivin MN, Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 2009;114(15):3181-90
   PubMed Web of Science ®Google Scholar
• Stirnemann J, Belmatoug N, Vincent C, Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther 2010;2(4):R156
   Google Scholar
• Bax BE, Richfield L, Bain MD, Haemorheology in Gaucher disease. Eur J Haematol 2005;75(3):252-8
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Barton NW, McKusick KA, Quantitative imaging of Gaucher disease. Radiology 1992;185(3):841-5
   PubMed Web of Science ®Google Scholar
• Hollak C, Maas M, Akkerman E, Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 2001;27(6):1005-12
   PubMed Web of Science ®Google Scholar
• Maas M, Hollak CE, Akkerman EM, Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 2002;179(4):961-5
   PubMedGoogle Scholar
• Johnson LA, Hoppel BE, Gerard EL, Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 1992;182(2):451-5
   PubMed Web of Science ®Google Scholar
• vom Dahl S, Poll L, Di Rocco M, Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin 2006;22(6):1045-64
   PubMed Web of Science ®Google Scholar
• Maas M, van Kuijk C, Stoker J, Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging–initial experience. Radiology 2003;229(2):554-61
   PubMed Web of Science ®Google Scholar
• Koo KH, Ahn IO, Kim R, Bone marrow edema and associated pain in early stage osteonecrosis of the femoral head: prospective study with serial MR images. Radiology 1999;213(3):715-22
   PubMed Web of Science ®Google Scholar
• Berger CE, Kroner A, Stiegler H, Hypofibrinolysis, lipoprotein(a), and plasminogen activator inhibitor. Clin Orthop 2002;397:342-9
   PubMedGoogle Scholar
• Hofmann S, Engel A, Neuhold A, Bone marrow oedema syndrome and transient osteoporosis of the hip. An MRI-controlled study of treatment by core decompression. J Bone Joint Surg 1993;75-Br:210-16
   Web of Science ®Google Scholar
• Hofmann S, Kramer J, Schneider W, Transient osteoporosis may represent a reversible early form of avascular necrosis of the hip joint. Curr Orthop 1997;11:164-72
   Google Scholar
• Mont MA, Hungerford DS. Current concepts review (nontraumatic avascular necrosis of the femoral head). J Bone Joint Surg 1995;77A:459-74
   Web of Science ®Google Scholar
• Ohzono K, Takaoka K, Saito S, Intraosseous arterial architecture in nontraumatic avascular necrosis of the femoral head. Microangiographic and histologic study. Clin Orthop Relat Res 1992;277:79-88
   PubMedGoogle Scholar
• Iida S, Harada Y, Shimizu K, Correlation between bone marrow edema and collapse of the femoral head in steroid-induced osteonecrosis. AJR Am J Roentgenol 2000;174:735-43
   PubMed Web of Science ®Google Scholar
• Berger CE, Kroner AH, Minai-Pour MB, Biochemical markers of bone metabolism in bone marrow edema syndrome of the hip. Bone 2003;33(3):346-51
   PubMed Web of Science ®Google Scholar
• Ciana G, Addobbati R, Tamaro G, Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 2005;28(5):723-32
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Mankin H, Dambrosia JM, Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 2002;28(2):288-96
   PubMed Web of Science ®Google Scholar
• Ciana G, Martini C, Leopaldi A, Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 2003;72(3):185-9
   PubMed Web of Science ®Google Scholar
• Drugan C, Jebeleanu G, Grigorescu-Sido P, Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2002;28(1):13-20
   PubMed Web of Science ®Google Scholar
• van Dussen L, Lips P, Everts VE, Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease. J Clin Endocrinol Metab 2011; published online 4 May 2011; doi:10.1210/jc.2011-0162
   PubMed Web of Science ®Google Scholar
• Rot A, Hub E, Middleton J, Some aspects of IL-8 pathophysiology. III: Chemokine interaction with endothelial cells. J Leukoc Biol 1996;59(1):39-44
   PubMed Web of Science ®Google Scholar
• Koch AE, Polverini PJ, Kunkel SL, Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258(5089):1798-801
   PubMed Web of Science ®Google Scholar
• Kraaijeveld AO, de Jager SC, de Jager WJ, CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007;116(17):1931-41
   PubMed Web of Science ®Google Scholar
• Hollak CE, vom Dahl S, Aerts JM, Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010;44:41-7
   PubMed Web of Science ®Google Scholar
• vom Dahl S, Poll LW, Haussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 2001;113(4):1084-7
   PubMed Web of Science ®Google Scholar
• Grinzaid KA, Geller E, Hanna SL, Cessation of enzyme replacement therapy in Gaucher disease. Genet Med 2001;4:427-33
   Web of Science ®Google Scholar
• Tothc J, Erdos M, Marodi L. Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur J Haematol 2003;70:125-8
   PubMed Web of Science ®Google Scholar
• Drelichman G, Ponce E, Basack N, Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr 2007;151:197-201
   PubMed Web of Science ®Google Scholar
• Giraldo P, Irun P, Alfonso P, Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis 2011;46(1):115-18
   PubMed Web of Science ®Google Scholar
• Elstein D, Granovsky-Grisaru S, Rabinowitz R, Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am J Obstet Gynecol 1997;177(6):1509-12
   PubMed Web of Science ®Google Scholar
• Elstein Y, Eisenberg V, Granovsky-Grisaru S, Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol 2004;190(2):435-41
   PubMed Web of Science ®Google Scholar